Verona Pharma plc Verona Pharma To Present At 2017 Wedbush Pacgrow Healthcare Conference

 
TIDMVRP TIDMVRP 
 
 
   LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, 
CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush 
PacGrow Healthcare Conference. 
 
   An audio webcast of the presentation will be available on the Investors 
section of the company website, www.veronapharma.com.  A replay of the 
webcast will be made available for 90 days following the presentation. 
 
   Event: Wedbush PacGrow Healthcare Conference 
 
   Date: August 15, 2017 
 
   Time: 3:05 PM EDT 
 
   Location: New York, NY 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. 
 
   Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, 
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as 
both a bronchodilator and an anti-inflammatory agent in a single 
compound. Verona Pharma is developing RPL554 for the treatment of 
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), 
and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                             Tel: [phone] 
Jan-Anders Karlsson, Chief Executive          [e-mail] 
Officer 
 
N+1 Singer (Nominated Adviser and UK          Tel: [phone] 
Broker) 
Aubrey Powell / James White 
 
FTI Consulting (UK Media and Investor         Tel: [phone] 
enquiries) 
Simon Conway / Stephanie Cuthbert /           [e-mail] 
 Natalie Garland-Collins 
 
ICR, Inc. (US Media and Investor 
enquiries) 
James Heins                                   Tel: [phone] 
                                               [e-mail] 
Stephanie Carrington                          Tel. [phone] 
                                               [e-mail] 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

August 01, 2017 07:05 ET (11:05 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.